Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

NCT07525258 | Recruiting

• 2 other identifiers: 20000387991K23AA031334-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

Conditions

Alcohol Use Disorder; Alcohol-associated Liver Disease

Keywords

Clinicians; Medications for Alcohol Use Disorder

Outcome Measures

Primary Outcomes (1)

• Feasibility

  Percentage of clinicians enrolled out of all recruited

  12 months

Secondary Outcomes (1)

• Acceptability

  12 months

Study Arms (1)

Hepatology Clinicians

EXPERIMENTAL

Clinician participants will participate in a multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. Participants will attend two approximately 60-minute-long educational sessions in which key points related to AUD treatment based on the HPCR resource and implementation facilitation intervention will be reviewed.

Behavioral: Implementation Intervention

Interventions

Implementation Intervention BEHAVIORAL

A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.

Hepatology Clinicians

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.

You may not qualify if:

• Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

Sponsors & Collaborators

• Yale University: lead
• National Institute on Alcohol Abuse and Alcoholism (NIAAA): collaborator

Study Sites (1)

Yale School of Medicine/Yale-New Haven Health

New Haven, Connecticut, 06520, United States

RECRUITING

MeSH Terms

Conditions

Alcoholism

Condition Hierarchy (Ancestors)

Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Lamia Haque

  Yale University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lamia Haque, MD MPH

CONTACT

(203) 777-0304; lamia.haque@yale.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Hepatology clinicians including attending physicians, trainees, and advanced practice providers will be invited to participate in an implementation facilitation intervention to improve AUD treatment in hepatology clinics. The interventions will include education, patient materials, clinical decision support tools and coaching/feedback.

Study Record Dates

• First Submitted: April 6, 2026
• First Posted: April 13, 2026
• Study Start: April 5, 2026
• Primary Completion (Estimated): April 1, 2029
• Study Completion (Estimated): April 1, 2029
• Last Updated: May 7, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)